APUS Financials: Apimeds Pharmaceuticals US Inc AI Analysis



Financials

APUS Financial

Apimeds Pharmaceuticals US Inc

0%

$0

At close: Jun 26, 16:00:00 GMT-4

0%

$0

Post-market: Jun 26, 18:32:28 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is APUS?

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	142	22	47	32	39	32
Revenue Growth (YoY)	-22%	-31%	-15%	-24%	-24%	-18%
Cost of Revenue	88	16	29	18	23	17
Gross Profit	54	6	17	14	16	14
Selling, General & Admin	118	24	32	31	30	35
Research & Development	--	--	--	--	--	--
Operating Expenses	126	25	34	33	32	37
Other Non Operating Income (Expenses)	5	2	2	0	1	0
Pretax Income	-75	-20	-19	-20	-15	-21
Income Tax Expense	0	0	0	0	0	0
Net Income	-76	-20	-19	-20	-15	-21
Net Income Growth	-13%	-5%	-27%	-5%	-21%	-22%
Shares Outstanding (Diluted)	8.73	8.73	8.35	8.16	8.09	8.02
Shares Change (YoY)	9%	9%	5%	3%	3%	3%
EPS (Diluted)	-8.71	-2.37	-2.34	-2.48	-1.91	-2.72
EPS Growth	-20%	-13%	-28%	-6%	-21%	-22%
Free Cash Flow	-41	-12	-4	-16	-9	-28
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	38.02%	27.27%	36.17%	43.75%	41.02%	43.75%
Operating Margin	-50.7%	-86.36%	-34.04%	-59.37%	-41.02%	-68.75%
Profit Margin	-53.52%	-90.9%	-40.42%	-62.5%	-38.46%	-65.62%
Free Cash Flow Margin	-28.87%	-54.54%	-8.51%	-50%	-23.07%	-87.5%
EBITDA	-65	-18	-14	-18	-15	-21
EBITDA Margin	-45.77%	-81.81%	-29.78%	-56.25%	-38.46%	-65.62%
D&A For EBITDA	7	1	2	1	1	1
EBIT	-72	-19	-16	-19	-16	-22
EBIT Margin	-50.7%	-86.36%	-34.04%	-59.37%	-41.02%	-68.75%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

142

Revenue Growth (YoY)

-22%

-31%

-15%

-24%

-18%

Cost of Revenue

Gross Profit

Selling, General & Admin

118

Research & Development

Operating Expenses

126

Other Non Operating Income (Expenses)

Pretax Income

-75

-20

-19

-20

-15

-21

Income Tax Expense

Net Income

-76

-20

-19

-20

-15

-21

Net Income Growth

-13%

-5%

-27%

-5%

-21%

-22%

Shares Outstanding (Diluted)

8.73

8.35

8.16

8.09

8.02

Shares Change (YoY)

EPS (Diluted)

-8.71

-2.37

-2.34

-2.48

-1.91

-2.72

EPS Growth

-20%

-13%

-28%

-6%

-21%

-22%

Free Cash Flow

-41

-12

-4

-16

-9

-28

Free Cash Flow Per Share

Gross Margin

38.02%

27.27%

36.17%

43.75%

41.02%

43.75%

Operating Margin

-50.7%

-86.36%

-34.04%

-59.37%

-41.02%

-68.75%

Profit Margin

-53.52%

-90.9%

-40.42%

-62.5%

-38.46%

-65.62%

Free Cash Flow Margin

-28.87%

-54.54%

-8.51%

-50%

-23.07%

-87.5%

EBITDA

-65

-18

-14

-18

-15

-21

EBITDA Margin

-45.77%

-81.81%

-29.78%

-56.25%

-38.46%

-65.62%

D&A For EBITDA

EBIT

-72

-19

-16

-19

-16

-22

EBIT Margin

-50.7%

-86.36%

-34.04%

-59.37%

-41.02%

-68.75%

Effective Tax Rate

Follow-Up Questions

What are Apimeds Pharmaceuticals US Inc's key financial statements?



According to the latest financial statement (Form-10K), Allbirds Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for APUS?



Allbirds Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Apimeds Pharmaceuticals US Inc's revenue broken down by segment or geography?



Allbirds Inc largest revenue segment is Footwear and Apparel Products, at a revenue of 152,466,000 in the most earnings release.For geography, United States is the primary market for Allbirds Inc, at a revenue of 118,621,000.

Is Apimeds Pharmaceuticals US Inc profitable?



no, according to the latest financial statements, Allbirds Inc has a net loss of $0

Does Apimeds Pharmaceuticals US Inc have any liabilities?



no, Allbirds Inc has liability of 0

How many outstanding shares for Apimeds Pharmaceuticals US Inc?



Allbirds Inc has a total outstanding shares of 0

Apimeds Pharmaceuticals US Inc (APUS) Financial

APUS Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is APUS?

Apimeds Pharmaceuticals US Inc (APUS) Financial

APUS Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is APUS?

APUS Income

Follow-Up Questions

What are Apimeds Pharmaceuticals US Inc's key financial statements?

What are the key financial ratios for APUS?

How is Apimeds Pharmaceuticals US Inc's revenue broken down by segment or geography?

Is Apimeds Pharmaceuticals US Inc profitable?

Does Apimeds Pharmaceuticals US Inc have any liabilities?

How many outstanding shares for Apimeds Pharmaceuticals US Inc?